Cargando…
Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset
BACKGROUND: Autoimmune thyroid disease (AITD) occurs in 40%–50% of alemtuzumab-treated persons with multiple sclerosis (pwMS), most of whom will develop Graves’ Disease (GD). OBJECTIVE: To explore contributory factors for alemtuzumab-related AITD in pwMS. METHODS: A retrospective patient chart revie...
Autores principales: | Yap, Siew Mei, Dillon, Mary, Crowley, Rachel K, McGuigan, Christopher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307483/ https://www.ncbi.nlm.nih.gov/pubmed/32612846 http://dx.doi.org/10.1177/2055217320933928 |
Ejemplares similares
-
Vaccine hesitancy among people with multiple sclerosis
por: Yap, Siew Mei, et al.
Publicado: (2021) -
Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
por: Alamo, Angela, et al.
Publicado: (2019) -
Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
por: Berger, Thomas, et al.
Publicado: (2016) -
Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016) -
Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients
por: Kazakou, Paraskevi, et al.
Publicado: (2021)